Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Free Cash Flow (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Free Cash Flow for 12 consecutive years, with -$9.0 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 16.63% year-over-year to -$9.0 million; the TTM value through Mar 2026 reached -$51.6 million, down 141.63%, while the annual FY2025 figure was -$71.5 million, 129.87% down from the prior year.
  • Free Cash Flow hit -$9.0 million in Q1 2026 for Crescent Biopharma, up from -$26.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$7.0 million in Q2 2023 and bottomed at -$26.0 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$11.9 million, with a median of -$10.5 million recorded in 2024.
  • Year-over-year, Free Cash Flow decreased 19.5% in 2022 and then skyrocketed 57.07% in 2023.
  • Crescent Biopharma's Free Cash Flow stood at -$7.9 million in 2022, then rose by 3.74% to -$7.6 million in 2023, then plummeted by 38.08% to -$10.5 million in 2024, then plummeted by 147.17% to -$26.0 million in 2025, then skyrocketed by 65.19% to -$9.0 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$9.0 million, -$26.0 million, and -$16.6 million for Q1 2026, Q4 2025, and Q2 2025 respectively.